熱門資訊> 正文
Shield结直肠癌筛查测试数据公布后Guardant下降
2025-09-04 20:35
- Guardant Health (NASDAQ:GH) lost ~9% in the premarket on Thursday after the company shared data from a clinical trial for its latest colorectal cancer (CRC) screening algorithm (V2) used in its Shield blood test.
- The study, an extension of Guardant’s registrational study ECLIPSE, met all primary endpoints, the company said, adding the screening algorithm helped detect 84% of cancers accurately (sensitivity) and correctly returned a negative result 90% of the time (specificity).
- Regarding stage I CRC, the V2 algorithm indicated 62% specificity, Guardant (NASDAQ:GH) added. Exact Sciences (NASDAQ:EXAS), the maker of stool-based colorectal cancer screening test Cologuard, added ~3% after the readout.
- ECLIPSE data, published in The New England Journal of Medicine, indicated 83% sensitivity for colorectal cancer, one of the co-primary endpoints of the trial, which was designed to test Shield in CRC detection among average-risk adults.
More on Guardant Health, Exact Sciences
- Exact Sciences Corporation (EXAS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
- Exact Sciences Corporation 2025 Q2 - Results - Earnings Call Presentation
- Exact Sciences Corporation (EXAS) Q2 2025 Earnings Call Transcript
- Exact Sciences withdraws injunction request for Cologuard rival
- Citi names TECH, WST, GH as top picks among life science tools & diagnostics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
